immatics appoints Dr. Harald Stock to its Board
Harald Stock has been Chief Executive Officer of the Grünenthal Group since January 2009. Previously, he was Chairman and Managing Director of the German DePuy Group, the orthopeadics division of Johnson & Johnson, from 2006 to the end of 2008. Between April and December 2008, he also represented Johnson & Johnson on the Board of BVMed, the German Medical Technology Industry Association.
Dr. Stock held senior management positions at Roche before being appointed Senior Vice President of the global Near Patient Testing Diagnostics Business in Graz, Austria in 2005. Dr. Stock holds degrees in Chemistry and Business Administration and has a PhD in chemistry from the University of Heidelberg.
"Harald's extensive experience within the healthcare industry and at the board level makes him a valuable addition to the immatics' team," says Thomas Widmann, Chairman of the Board of immatics. "I am confident that his knowledge and counsel will help the Company achieve its next set of value creating clinical and business development milestones."
"I am extremely excited to joining the Board of immatics, a fast emerging company in the field of therapeutic cancer vaccines," says Harald Stock. "The positive survival benefits that have been seen in renal cell carcinoma patients with the Company's lead vaccine IMA-901, along with its strong financial position and talented management team have clearly positioned immatics for success."
immatics biotechnologies GmbH
immatics biotechnologies is a clinical-stage biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer. immatics' lead product, IMA901, has completed a successful phase II trial in renal cell carcinoma. immatics' pipeline also includes IMA910, in phase II for colorectal cancer, and IMA950 which is in phase I for glioma.
immatics' XPRESIDENT(TM) technology platform rapidly generates defined therapeutic cancer vaccines, based on multiple tumor-associated peptides (TUMAPs), that have the ability to specifically stimulate the immune system against cancer cells. These vaccines - comprising multiple peptides confirmed to be naturally presented by real tumor tissue - offer the prospect of greater effectiveness than existing cancer vaccine approaches. immatics' products are 'drug like' with stable, off-the-shelf formulations and robust easily scalable manufacturing.
immatics is based in Tuebingen and Munich, Germany, and has raised more than €100 million (US$130million) in private equity in three financing rounds since 2004.